1. Scrip
  2. >>Therapy Areas

Novartis Upbeat As Ofatumumab Data Delivers In MS

 
• By Kevin Grogan

Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.

Home_Shelf
If approved, ofatumumab could be self-administered at home • Source: Shutterstock

Novartis AG has presented detailed data on its latest multiple sclerosis drug ofatumumab which the company believes will provide a more convenient treatment for patients than Roche's rival therapy Ocrevus.

Having published positive topline results last month, Novartis presented the full data set from the Phase III ASCLEPIOS I and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.